Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18262007 | 0.84 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL18487257 | 0.84 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL18262010 | 0.84 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL2404127 | 0.84 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL14701547 | 0.83 | CTSK (0.51) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL7722427 | 0.83 | CTSK (0.51) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL7722431 | 0.83 | CTSK (0.51) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL248984 | 0.83 | TDP1 (0.48) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL3853568 | 0.81 | TDP1 (0.47) | TDP1MEN1GAAKMT2ACTSK | |
| SCHEMBL8775013 | 0.81 | TDP1 (0.47) | TDP1MEN1GAAKMT2ACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0007470-B1 | CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-10-12 | — | — | EP | claimed |
| US-4268509-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-19 | — | — | US | claimed |
| EP-0007470-A2 | Cephem compounds, processes for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-02-06 | — | — | EP | claimed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-114057771-B | Macrocyclic compounds, their preparation and use | 北京鞍石生物科技有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023109942-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-114057771-A | Macrocyclic compound and preparation method and application thereof | 北京鞍石生物科技有限责任公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11090322-B2 | Anthracycline disulfide intermediates, antibody-drug conjugates and methods | GENENTECH, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| CN-113166101-A | Cyclic pentameric compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-1169792-C | Substituted vinylpyridine derivatives and medicaments containing them | ������ҩ��ʽ���� | 2004-10-06 | — | — | CN | disclosed |
| CN-1411444-A | Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same | SEUWIEL LAB (FR) | 2003-04-16 | — | — | CN | disclosed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| CN-1206407-A | Substituted vinylpyridine derivatives and medicaments containing them | SS PHARMACEUTICAL CO (JP) | 1999-01-27 | — | — | CN | disclosed |
| US-4585872-A | CEPHALOSPORIN ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| EP-0036673-B1 | NEW THIADIAZOL COMPOUNDS AND PROCESSES FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-11 | — | — | EP | disclosed |
| US-4447429-A | ANTIBIOTICS, BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-08 | — | — | US | disclosed |
| EP-0007470-B1 | CEPHEM COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-10-12 | — | — | EP | disclosed |
| US-4268509-A | BACTERICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | TDP1 1467/4885MEN1 1044/4885GAA 366/4885 |
| US-11090322-B2 | Anthracycline disulfide intermediates, antibody-drug conjugates and methods | PDIA5, PDIA4, PDIA6 | TDP1 4120/4885MEN1 4005/4885GAA 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.